Free Trial
→ A grave, grave error. (From Porter & Company) (Ad) Buy JANX Stock  Free JANX Stock Alerts

Janux Therapeutics (JANX) Financials

Janux Therapeutics logo
$23.71 -0.33 (-1.37%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$24.48 +0.77 (+3.25%)
As of 05/30/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Janux Therapeutics

Annual Income Statements for Janux Therapeutics

This table shows Janux Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Net Income / (Loss) Attributable to Common Shareholders		 -69 -58 -63 -33 -8.73
Consolidated Net Income / (Loss)		 -69 -58 -63 -33 -6.78
Net Income / (Loss) Continuing Operations		 -69 -58 -63 -33 -8.73
Total Pre-Tax Income 		-69 -58 -63 -33 -8.73
Total Operating Income		 -99 -73 -67 -33 -4.84
Total Gross Profit		 11 8.08 8.61 3.64 0.00
Total Revenue		 11 8.08 8.61 3.64 0.00
Operating Revenue		 11 8.08 8.61 3.64 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 109 81 76 37 4.84
Selling, General & Admin Expense		 41 26 22 10 1.80
Research & Development Expense		 68 55 53 26 3.04
Total Other Income / (Expense), net		 30 15 4.03 0.26 -3.88
Interest & Investment Income		 30 15 4.03 0.26 0.00
Basic Earnings per Share		 ($1.28) ($1.32) ($1.52) ($1.39) ($7.41)
Weighted Average Basic Shares Outstanding		 53.75M 44.02M 41.47M 23.53M 915.15K
Diluted Earnings per Share		 ($1.28) ($1.32) ($1.52) ($1.39) ($7.41)
Weighted Average Diluted Shares Outstanding		 53.75M 44.02M 41.47M 23.53M 915.15K
Weighted Average Basic & Diluted Shares Outstanding		 59.11M 51.66M 41.83M 23.53M 915.15K

Quarterly Income Statements for Janux Therapeutics

This table shows Janux Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -24 -20 -28 -5.96 -15 -12 -12 -18 -17 -16 -17
Consolidated Net Income / (Loss)		 -24 -20 -28 -5.96 -15 -12 -12 -18 -17 -16 -17
Net Income / (Loss) Continuing Operations		 -24 -20 -28 -5.96 -15 -12 -12 -18 -17 -16 -17
Total Pre-Tax Income 		-24 -20 -28 -5.96 -15 -12 -12 -18 -17 -16 -17
Total Operating Income		 -35 -29 -36 -14 -20 -16 -16 -21 -20 -18 -18
Total Gross Profit		 0.00 - 0.44 8.90 1.25 2.46 2.52 1.06 2.05 2.85 1.81
Total Revenue		 0.00 - 0.44 8.90 1.25 2.46 2.52 1.06 2.05 2.85 1.81
Operating Revenue		 0.00 - 0.44 8.90 1.25 2.46 2.52 1.06 2.05 2.85 1.81
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 35 29 36 23 21 19 18 22 22 21 20
Selling, General & Admin Expense		 9.84 8.22 18 7.82 7.34 6.36 6.44 6.88 6.46 5.68 6.10
Research & Development Expense		 25 21 19 15 14 12 12 15 16 15 14
Total Other Income / (Expense), net		 11 8.81 7.78 7.86 5.40 4.38 4.25 3.24 2.82 2.07 1.33
Interest & Investment Income		 11 8.81 7.78 7.86 5.40 4.38 4.25 3.24 2.82 2.20 1.33
Basic Earnings per Share		 ($0.38) ($0.36) ($0.51) ($0.11) ($0.30) ($0.23) ($0.25) ($0.42) ($0.42) ($0.39) ($0.40)
Weighted Average Basic Shares Outstanding		 61.79M 53.75M 54.63M 54.45M 49.05M 44.02M 45.71M 41.84M 41.76M 41.47M 41.53M
Diluted Earnings per Share		 ($0.38) ($0.36) ($0.51) ($0.11) ($0.30) ($0.23) ($0.25) ($0.42) ($0.42) ($0.39) ($0.40)
Weighted Average Diluted Shares Outstanding		 61.79M 53.75M 54.63M 54.45M 49.05M 44.02M 45.71M 41.84M 41.76M 41.47M 41.53M
Weighted Average Basic & Diluted Shares Outstanding		 59.18M 59.11M 52.48M 52.16M 51.85M 51.66M 46.17M 46.14M 41.83M 41.83M 41.66M

Annual Cash Flow Statements for Janux Therapeutics

This table details how cash moves in and out of Janux Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Net Change in Cash & Equivalents		 411 -32 16 29 7.16
Net Cash From Operating Activities		 -44 -51 -43 -17 -4.37
Net Cash From Continuing Operating Activities		 -44 -51 -43 -17 -4.37
Net Income / (Loss) Continuing Operations		 -69 -58 -63 -33 -6.78
Consolidated Net Income / (Loss)		 -69 -58 -63 -33 -6.78
Depreciation Expense		 2.06 1.96 0.84 0.11 0.01
Amortization Expense		 -11 -7.69 -2.18 -0.17 0.00
Non-Cash Adjustments To Reconcile Net Income		 33 20 17 6.91 2.01
Changes in Operating Assets and Liabilities, net		 0.69 -6.55 4.28 8.84 0.39
Net Cash From Investing Activities		 -258 -41 58 -341 0.00
Net Cash From Continuing Investing Activities		 -258 -41 58 -341 0.00
Purchase of Property, Plant & Equipment		 -0.36 -1.85 -6.45 -1.48 0.00
Purchase of Investments		 -471 -317 -294 -474 0.00
Sale and/or Maturity of Investments		 213 278 359 134 0.00
Net Cash From Financing Activities		 713 60 0.50 387 12
Net Cash From Continuing Financing Activities		 713 60 0.50 387 12
Issuance of Common Equity		 698 57 0.00 204 0.00
Other Financing Activities, net		 15 3.02 0.50 1.81 0.07

Quarterly Cash Flow Statements for Janux Therapeutics

This table details how cash moves in and out of Janux Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -357 404 12 -198 194 2.05 -17 3.35 -21 -13 6.35
Net Cash From Operating Activities		 -17 -17 -2.23 -10 -15 -9.90 -12 -15 -14 -12 -13
Net Cash From Continuing Operating Activities		 -17 -17 -2.23 -10 -15 -9.90 -12 -15 -14 -12 -13
Net Income / (Loss) Continuing Operations		 -24 -20 -28 -5.96 -15 -12 -12 -18 -17 -16 -17
Consolidated Net Income / (Loss)		 -24 -20 -28 -5.96 -15 -12 -12 -18 -17 -16 -17
Depreciation Expense		 0.52 0.51 0.51 0.51 0.53 0.53 0.50 0.47 0.45 0.40 0.25
Amortization Expense		 -4.22 -2.93 -2.90 -2.97 -1.79 -2.06 -2.11 -1.84 -1.68 -1.29 -0.77
Non-Cash Adjustments To Reconcile Net Income		 11 6.25 15 5.76 5.63 4.48 4.55 5.50 5.47 4.21 4.60
Changes in Operating Assets and Liabilities, net		 -0.52 -0.35 13 -7.35 -4.45 -1.10 -3.08 -1.68 -0.70 0.84 -0.80
Net Cash From Investing Activities		 -340 34 13 -191 -114 11 -61 18 -8.74 -1.60 20
Net Cash From Continuing Investing Activities		 -340 34 13 -191 -114 11 -61 18 -8.74 -1.60 20
Purchase of Property, Plant & Equipment		 -0.37 -0.04 -0.03 -0.10 -0.20 -0.52 -0.47 -0.58 -0.29 -2.06 -2.52
Purchase of Investments		 -371 -24 -32 -236 -179 -33 -136 -77 -72 -86 -94
Sale and/or Maturity of Investments		 31 58 45 45 65 45 75 95 63 87 117
Net Cash From Financing Activities		 0.55 387 1.65 2.77 322 0.83 57 0.53 1.58 0.19 -
Net Cash From Continuing Financing Activities		 0.55 387 1.65 2.77 322 0.83 57 0.53 1.58 0.19 -
Issuance of Common Equity		 -0.35 378 - -0.46 321 - 57 - 0.00 - -
Other Financing Activities, net		 0.90 8.44 1.65 3.22 1.66 0.83 0.08 0.53 1.58 0.19 -

Annual Balance Sheets for Janux Therapeutics

This table presents Janux Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Total Assets		 1,062 380 364 380 16
Total Current Assets		 1,034 349 332 377 16
Cash & Equivalents		 431 19 51 36 7.81
Short-Term Investments		 595 325 276 339 0.00
Prepaid Expenses		 8.49 5.21 5.42 2.05 0.25
Plant, Property, & Equipment, net		 4.86 7.00 7.09 1.41 0.16
Total Noncurrent Assets		 23 24 24 1.39 0.00
Other Noncurrent Operating Assets		 23 24 24 1.39 0.00
Total Liabilities & Shareholders' Equity		 1,062 380 364 380 16
Total Liabilities		 39 36 43 13 9.23
Total Current Liabilities		 17 13 17 13 3.18
Accounts Payable		 4.03 2.42 2.16 2.46 0.43
Accrued Expenses		 12 7.39 8.18 3.78 0.75
Current Deferred Revenue		 0.00 1.71 5.41 5.16 1.95
Other Current Liabilities		 1.75 1.52 0.76 1.40 0.05
Total Noncurrent Liabilities		 21 23 27 0.70 6.05
Noncurrent Deferred Revenue		 0.00 0.00 2.22 0.70 6.05
Other Noncurrent Operating Liabilities		 21 23 25 0.00 -
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,023 344 321 366 -15
Total Preferred & Common Equity		 1,023 344 321 366 -15
Preferred Stock		 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,023 344 321 366 -15
Common Stock		 1,258 512 433 414 0.10
Retained Earnings		 -238 -169 -110 -47 -15
Accumulated Other Comprehensive Income / (Loss)		 2.16 0.67 -1.54 -0.27 0.00

Quarterly Balance Sheets for Janux Therapeutics

This table presents Janux Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 1,051 695 691 689 387 342 353 376
Total Current Assets		 1,023 666 662 659 355 309 321 344
Cash & Equivalents		 74 27 15 213 17 34 30 65
Short-Term Investments		 940 631 632 439 333 270 287 274
Prepaid Expenses		 9.19 8.29 8.15 6.38 5.48 6.01 3.77 5.07
Plant, Property, & Equipment, net		 4.95 5.37 5.94 6.52 7.32 7.38 7.20 6.51
Total Noncurrent Assets		 22 23 24 24 24 25 24 25
Other Noncurrent Operating Assets		 22 23 24 24 24 25 24 25
Total Liabilities & Shareholders' Equity		 1,051 695 691 689 387 342 353 376
Total Liabilities		 38 39 34 33 38 42 42 44
Total Current Liabilities		 18 17 12 11 14 18 16 16
Accounts Payable		 2.35 2.46 1.25 2.25 2.51 1.91 2.05 2.87
Accrued Expenses		 13 13 8.57 5.81 6.83 9.22 7.74 7.24
Current Deferred Revenue		 0.00 0.00 0.09 0.97 3.65 5.34 4.94 5.91
Other Current Liabilities		 1.81 1.69 1.63 1.57 1.49 1.44 1.39 0.32
Total Noncurrent Liabilities		 21 22 22 23 23 24 26 28
Noncurrent Deferred Revenue		 0.00 0.00 0.00 0.00 0.00 0.31 1.39 3.82
Other Noncurrent Operating Liabilities		 21 22 22 23 23 24 24 24
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,012 656 658 656 349 299 311 332
Total Preferred & Common Equity		 1,012 656 658 656 349 299 311 332
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,012 656 658 656 349 299 311 332
Common Stock		 1,270 866 849 840 507 446 440 428
Retained Earnings		 -261 -218 -189 -184 -157 -145 -128 -94
Accumulated Other Comprehensive Income / (Loss)		 3.76 7.83 -1.62 -0.52 -1.18 -1.06 -0.74 -2.28

Annual Metrics And Ratios for Janux Therapeutics

This table displays calculated financial ratios and metrics derived from Janux Therapeutics' official financial filings.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Growth Metrics		 - - - - -
Revenue Growth		 30.99% -6.14% 136.79% 0.00% 0.00%
EBITDA Growth		 -36.41% -15.02% -107.45% -287.82% 0.00%
EBIT Growth		 -35.45% -8.78% -103.74% -286.54% 0.00%
NOPAT Growth		 -35.45% -8.78% -103.74% -579.93% 0.00%
Net Income Growth		 -18.36% 7.56% -93.01% -381.60% 0.00%
EPS Growth		 3.03% 13.16% -9.35% 81.24% 0.00%
Operating Cash Flow Growth		 13.37% -17.83% -152.84% -288.56% 0.00%
Free Cash Flow Firm Growth		 -15.25% -16.94% -223.67% 0.00% 0.00%
Invested Capital Growth		 -845.17% 105.11% 27.34% -944.50% 0.00%
Revenue Q/Q Growth		 -18.86% -4.54% 16.65% 0.00% 0.00%
EBITDA Q/Q Growth		 -14.71% 1.86% -9.04% 0.00% 0.00%
EBIT Q/Q Growth		 -14.99% 2.83% -7.66% 0.00% 0.00%
NOPAT Q/Q Growth		 -14.99% 2.83% -7.66% 0.00% 0.00%
Net Income Q/Q Growth		 -13.97% 6.88% -4.39% 0.00% 0.00%
EPS Q/Q Growth		 -11.30% 10.81% -461.90% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -18.45% 3.83% -3.45% -108.96% 0.00%
Free Cash Flow Firm Q/Q Growth		 -12.66% 2.33% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 -24.13% 142.02% 13.40% 0.00% 0.00%
Profitability Metrics		 - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 0.00%
EBITDA Margin		 -1,014.09% -973.80% -794.62% -907.01% 0.00%
Operating Margin		 -933.58% -902.87% -779.04% -905.39% 0.00%
EBIT Margin		 -933.58% -902.87% -779.04% -905.39% 0.00%
Profit (Net Income) Margin		 -651.62% -721.18% -732.22% -898.32% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 77.75%
Interest Burden Percent		 69.80% 79.88% 93.99% 99.22% 102.42%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -10.09% -17.53% -18.36% -17.50% -97.11%
Cash Return on Invested Capital (CROIC)		 0.00% -17,969.56% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -13.71% -19.61% -18.04% -16.63% 0.00%
Return on Assets (ROA)		 -9.57% -15.66% -16.96% -16.50% 0.00%
Return on Common Equity (ROCE)		 -10.09% -17.53% -18.36% -16.49% 203.47%
Return on Equity Simple (ROE_SIMPLE)		 -6.75% -16.93% -19.66% -8.92% 46.35%
Net Operating Profit after Tax (NOPAT)		 -69 -51 -47 -23 -3.39
NOPAT Margin		 -653.50% -632.01% -545.33% -633.77% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.03% -2.15% -4.59% -5.03% -43.44%
Return On Investment Capital (ROIC_SIMPLE)		 -6.77% -14.84% -14.64% - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 387.67% 323.39% 258.50% 284.00% 0.00%
R&D to Revenue		 645.90% 679.48% 620.54% 721.39% 0.00%
Operating Expenses to Revenue		 1,033.58% 1,002.87% 879.04% 1,005.39% 0.00%
Earnings before Interest and Taxes (EBIT)		 -99 -73 -67 -33 -8.52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -107 -79 -68 -33 -8.51
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 2.75 1.44 1.71 2.24 0.00
Price to Tangible Book Value (P/TBV)		 2.75 1.44 1.71 2.24 0.00
Price to Revenue (P/Rev)		 265.38 61.29 63.71 225.73 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 471.52 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 168.56 18.73 25.74 122.64 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.00 -1.01 -1.02 -1.03 -1.12
Leverage Ratio		 1.05 1.12 1.08 1.06 2.32
Compound Leverage Factor		 0.74 0.89 1.02 1.05 2.38
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 309.53%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% -209.53%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 44.06 8.07 7.64 37.20 10.54
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 5.79% 309.53%
Liquidity Ratios		 - - - - -
Current Ratio		 59.21 26.80 20.14 29.46 5.05
Quick Ratio		 58.72 26.40 19.81 29.30 4.97
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 -66 -58 -49 -15 0.00
Operating Cash Flow to CapEx		 -12,204.46% -2,733.78% -665.97% -1,145.48% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 -21.21
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -21.21
Efficiency Ratios		 - - - - -
Asset Turnover		 0.01 0.02 0.02 0.02 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.78 1.15 2.03 4.64 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - -
Invested Capital		 -2.39 0.32 -6.28 -8.64 -0.83
Invested Capital Turnover		 -10.23 -2.71 -1.15 -0.77 0.00
Increase / (Decrease) in Invested Capital		 -2.71 6.60 2.36 -7.81 0.00
Enterprise Value (EV)		 1,785 151 222 446 208
Market Capitalization		 2,810 495 549 821 194
Book Value per Share		 $19.49 $7.46 $7.70 $8.80 ($16.00)
Tangible Book Value per Share		 $19.49 $7.46 $7.70 $8.80 ($16.00)
Total Capital		 1,023 344 321 366 6.99
Total Debt		 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00
Net Debt		 -1,025 -344 -327 -375 -7.81
Capital Expenditures (CapEx)		 0.36 1.85 6.45 1.48 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.97 -7.82 -11 -11 5.07
Debt-free Net Working Capital (DFNWC)		 1,016 336 316 364 13
Net Working Capital (NWC)		 1,016 336 316 364 13
Net Nonoperating Expense (NNE)		 -0.20 7.21 16 9.62 3.39
Net Nonoperating Obligations (NNO)		 -1,025 -344 -327 -375 -7.81
Total Depreciation and Amortization (D&A)		 -8.53 -5.73 -1.34 -0.06 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 -84.68% -96.75% -128.70% -295.38% 0.00%
Debt-free Net Working Capital to Revenue		 9,597.72% 4,159.45% 3,668.51% 10,014.35% 0.00%
Net Working Capital to Revenue		 9,597.72% 4,159.45% 3,668.51% 10,014.35% 0.00%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 ($1.28) ($1.32) ($1.52) ($1.39) $0.00
Adjusted Weighted Average Basic Shares Outstanding		 53.75M 44.02M 41.47M 41.62M 0.00
Adjusted Diluted Earnings per Share		 ($1.28) ($1.32) ($1.52) ($1.39) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 53.75M 44.02M 41.47M 41.62M 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($1.39) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 59.11M 51.66M 41.83M 23.53M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -69 -51 -47 -23 -3.39
Normalized NOPAT Margin		 -653.50% -632.01% -545.33% -633.77% 0.00%
Pre Tax Income Margin		 -651.62% -721.18% -732.22% -898.32% 0.00%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 -41.35
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 -16.46
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -41.35
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -16.46
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Janux Therapeutics

This table displays calculated financial ratios and metrics derived from Janux Therapeutics' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -100.00% 0.00% -82.56% 741.72% -38.87% -13.50% 38.83% -55.31% 28.89% 76.05% 56.43%
EBITDA Growth		 -80.23% -77.94% -119.45% 26.35% 0.42% 7.77% 6.04% -28.21% -61.06% -42.06% -69.25%
EBIT Growth		 -73.09% -79.85% -126.66% 33.38% 0.59% 11.66% 12.26% -20.20% -51.24% -35.40% -65.29%
NOPAT Growth		 -73.09% -79.85% -126.66% 33.38% 0.59% 11.66% 12.26% -20.20% -49.76% -35.40% -65.29%
Net Income Growth		 -59.27% -71.93% -142.56% 65.96% 15.46% 26.81% 30.71% -3.67% -30.19% -19.75% -55.08%
EPS Growth		 -26.67% -56.52% -104.00% 73.81% 28.57% 41.03% 37.50% -2.44% -31.25% -125.16% -53.85%
Operating Cash Flow Growth		 -14.74% -68.92% 80.95% 33.43% -6.66% 16.89% 12.71% -147.88% -20.73% -13.66% -129.14%
Free Cash Flow Firm Growth		 20.96% 1.62% -36.32% -17.44% -63.39% -18.12% -8.85% -92.58% -309.54% 0.00% -616.03%
Invested Capital Growth		 -141.93% -845.17% -152.23% 398.01% 171.29% 105.11% 89.46% 63.56% 5.44% 27.34% 32.63%
Revenue Q/Q Growth		 0.00% 0.00% -95.07% 610.62% -49.13% -2.22% 138.13% -48.39% -28.01% 56.92% -23.34%
EBITDA Q/Q Growth		 -22.78% 17.77% -134.70% 23.94% -21.22% -1.41% 21.24% -2.85% -12.27% -3.31% -7.47%
EBIT Q/Q Growth		 -20.24% 19.03% -159.31% 31.44% -24.94% -2.05% 23.79% -2.30% -11.03% -1.35% -4.41%
NOPAT Q/Q Growth		 -20.24% 19.03% -159.31% 31.44% -24.94% -2.05% 23.79% -2.30% -11.03% -1.35% -4.41%
Net Income Q/Q Growth		 -16.28% 27.95% -370.87% 59.63% -25.53% -1.64% 33.93% -0.28% -8.68% 3.78% 1.14%
EPS Q/Q Growth		 -5.56% 29.41% -363.64% 63.33% -30.43% 8.00% 40.48% 0.00% -7.69% 2.50% 2.44%
Operating Cash Flow Q/Q Growth		 -1.79% -649.66% 77.74% 32.46% -49.85% 15.44% 22.22% -8.22% -16.77% 11.19% -120.88%
Free Cash Flow Firm Q/Q Growth		 -6.52% 26.43% 3.83% -4.87% -32.59% -1.94% 17.15% -45.91% 4.15% 6.06% -46.59%
Invested Capital Q/Q Growth		 29.89% -24.13% -116.93% 184.60% 1,146.11% 142.02% 80.00% 31.92% 10.60% 13.40% 30.86%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% -8,708.43% -183.08% -1,710.54% -717.88% -692.13% -2,092.53% -1,050.10% -673.29% -1,022.67%
Operating Margin		 0.00% 0.00% -8,164.46% -155.36% -1,610.30% -655.71% -628.25% -1,962.91% -990.28% -642.04% -994.04%
EBIT Margin		 0.00% 0.00% -8,164.46% -155.36% -1,610.30% -655.71% -628.25% -1,962.91% -990.28% -642.04% -994.04%
Profit (Net Income) Margin		 0.00% 0.00% -6,391.57% -66.98% -1,178.91% -477.77% -459.59% -1,656.39% -852.49% -564.67% -920.90%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.19% 100.00%
Interest Burden Percent		 67.36% 69.66% 78.29% 43.11% 73.21% 72.86% 73.16% 84.38% 86.09% 88.67% 92.64%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -434.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -435.75% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 432.31% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -10.09% -12.05% -2.66% -11.50% -17.53% -18.40% -21.06% -20.11% -18.36% -17.06%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -538.98% -1,515.31% -17,969.56% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% -196.95% -4.55% -22.52% -14.24% -13.95% -41.93% -24.90% -14.87% -19.14%
Return on Assets (ROA)		 0.00% 0.00% -154.18% -1.96% -16.49% -10.38% -10.21% -35.38% -21.43% -13.08% -17.73%
Return on Common Equity (ROCE)		 0.00% -10.09% -12.05% -2.66% -11.50% -17.53% -18.40% -21.06% -20.11% -18.36% -17.06%
Return on Equity Simple (ROE_SIMPLE)		 -7.68% 0.00% -9.23% -6.70% -8.48% 0.00% -17.94% -22.62% -21.56% 0.00% -18.22%
Net Operating Profit after Tax (NOPAT)		 -24 -20 -25 -9.68 -14 -11 -11 -15 -14 -13 -13
NOPAT Margin		 0.00% 0.00% -5,715.13% -108.75% -1,127.21% -459.00% -439.77% -1,374.04% -693.20% -449.43% -695.83%
Net Nonoperating Expense Percent (NNEP)		 0.11% 0.01% -0.59% 0.78% -0.13% -0.14% -0.14% -0.91% -0.96% -0.93% -1.12%
Return On Investment Capital (ROIC_SIMPLE)		 -2.41% -1.99% - - - -3.28% - - - -3.99% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 4,024.37% 87.91% 586.50% 258.31% 255.78% 650.99% 315.63% 199.54% 336.35%
R&D to Revenue		 0.00% 0.00% 4,240.09% 167.45% 1,123.80% 497.40% 472.47% 1,411.92% 774.66% 542.50% 757.69%
Operating Expenses to Revenue		 0.00% 0.00% 8,264.46% 255.36% 1,710.30% 755.71% 728.25% 2,062.91% 1,090.28% 742.04% 1,094.04%
Earnings before Interest and Taxes (EBIT)		 -35 -29 -36 -14 -20 -16 -16 -21 -20 -18 -18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -39 -31 -38 -16 -21 -18 -17 -22 -22 -19 -19
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.58 2.75 3.61 3.30 2.97 1.44 1.33 1.66 1.63 1.71 1.70
Price to Tangible Book Value (P/TBV)		 1.58 2.75 3.61 3.30 2.97 1.44 1.33 1.66 1.63 1.71 1.70
Price to Revenue (P/Rev)		 170.93 265.38 181.61 143.59 266.91 61.29 54.93 63.97 55.80 63.71 76.41
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 134.02 323.31 471.52 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 62.31 168.56 131.18 100.86 177.47 18.73 13.63 24.90 20.87 25.74 30.52
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.00 -1.00 -1.00 -0.99 -1.00 -1.01 -1.01 -1.02 -1.02 -1.02 -1.03
Leverage Ratio		 1.04 1.05 1.08 1.08 1.08 1.12 1.12 1.13 1.08 1.08 1.08
Compound Leverage Factor		 0.70 0.73 0.84 0.47 0.79 0.82 0.82 0.95 0.93 0.96 1.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 25.70 44.28 37.07 39.33 35.80 8.56 7.74 7.34 7.65 8.08 8.21
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 58.47 59.21 38.80 57.34 62.09 26.80 24.55 17.28 19.95 20.14 21.08
Quick Ratio		 57.94 58.72 38.32 56.63 61.48 26.40 24.17 16.94 19.71 19.81 20.77
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -19 -18 -24 -25 -24 -18 -18 -21 -15 -15 -16
Operating Cash Flow to CapEx		 -4,588.68% -39,821.43% -8,924.00% -10,548.42% -7,531.47% -1,922.52% -2,491.28% -2,595.52% -4,881.05% -579.43% -532.30%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.01 0.02 0.03 0.01 0.02 0.02 0.02 0.03 0.02 0.02
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 11.48 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.63 1.78 2.06 2.27 1.06 1.15 1.22 1.43 1.84 2.03 1.93
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 31.78 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 31.78 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.68 -2.39 -1.93 11 4.00 0.32 -0.76 -3.82 -5.61 -6.28 -7.25
Invested Capital Turnover		 8.04 -10.23 -9.70 4.00 -9.05 -2.71 -2.11 -1.09 -1.57 -1.15 -0.82
Increase / (Decrease) in Invested Capital		 -5.68 -2.71 -1.16 15 9.61 6.60 6.48 6.66 0.32 2.36 3.51
Enterprise Value (EV)		 582 1,785 1,712 1,526 1,293 151 115 193 189 222 225
Market Capitalization		 1,596 2,810 2,370 2,172 1,945 495 465 497 506 549 564
Book Value per Share		 $17.13 $19.49 $12.58 $12.68 $12.69 $7.46 $7.56 $7.16 $7.44 $7.70 $7.96
Tangible Book Value per Share		 $17.13 $19.49 $12.58 $12.68 $12.69 $7.46 $7.56 $7.16 $7.44 $7.70 $7.96
Total Capital		 1,012 1,023 656 658 656 344 349 299 311 321 332
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -1,014 -1,025 -658 -646 -652 -344 -350 -303 -317 -327 -339
Capital Expenditures (CapEx)		 0.37 0.04 0.03 0.10 0.20 0.52 0.47 0.58 0.29 2.06 2.52
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.31 -8.97 -8.88 4.10 -3.71 -7.82 -8.99 -12 -12 -11 -11
Debt-free Net Working Capital (DFNWC)		 1,006 1,016 649 650 648 336 341 291 305 316 328
Net Working Capital (NWC)		 1,006 1,016 649 650 648 336 341 291 305 316 328
Net Nonoperating Expense (NNE)		 -0.92 -0.10 2.97 -3.72 0.65 0.46 0.50 2.98 3.26 3.28 4.08
Net Nonoperating Obligations (NNO)		 -1,014 -1,025 -658 -646 -652 -344 -350 -303 -317 -327 -339
Total Depreciation and Amortization (D&A)		 -3.70 -2.42 -2.39 -2.47 -1.26 -1.53 -1.61 -1.37 -1.23 -0.89 -0.52
Debt-free, Cash-free Net Working Capital to Revenue		 -89.00% -84.68% -68.07% 27.11% -50.86% -96.75% -106.15% -153.18% -127.77% -128.70% -145.81%
Debt-free Net Working Capital to Revenue		 10,773.75% 9,597.72% 4,974.70% 4,299.56% 8,893.33% 4,159.45% 4,024.14% 3,753.68% 3,365.51% 3,668.51% 4,442.57%
Net Working Capital to Revenue		 10,773.75% 9,597.72% 4,974.70% 4,299.56% 8,893.33% 4,159.45% 4,024.14% 3,753.68% 3,365.51% 3,668.51% 4,442.57%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.38) ($0.36) ($0.51) ($0.11) ($0.30) ($0.23) ($0.25) ($0.42) ($0.42) ($0.39) ($0.40)
Adjusted Weighted Average Basic Shares Outstanding		 61.79M 53.75M 54.63M 54.45M 49.05M 44.02M 45.71M 41.84M 41.76M 41.47M 41.53M
Adjusted Diluted Earnings per Share		 ($0.38) ($0.36) ($0.51) ($0.11) ($0.30) ($0.23) ($0.25) ($0.42) ($0.42) ($0.39) ($0.40)
Adjusted Weighted Average Diluted Shares Outstanding		 61.79M 53.75M 54.63M 54.45M 49.05M 44.02M 45.71M 41.84M 41.76M 41.47M 41.53M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 59.18M 59.11M 52.48M 52.16M 51.85M 51.66M 46.17M 46.14M 41.83M 41.83M 41.66M
Normalized Net Operating Profit after Tax (NOPAT)		 -24 -20 -25 -9.68 -14 -11 -11 -15 -14 -13 -13
Normalized NOPAT Margin		 0.00% 0.00% -5,715.13% -108.75% -1,127.21% -459.00% -439.77% -1,374.04% -693.20% -449.43% -695.83%
Pre Tax Income Margin		 0.00% 0.00% -6,391.57% -66.98% -1,178.91% -477.77% -459.59% -1,656.39% -852.49% -569.31% -920.90%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Janux Therapeutics' Financials

When does Janux Therapeutics's financial year end?

According to the most recent income statement we have on file, Janux Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Janux Therapeutics' net income changed over the last 4 years?

Janux Therapeutics' net income appears to be on an upward trend, with a most recent value of -$68.99 million in 2024, rising from -$6.78 million in 2020. The previous period was -$58.29 million in 2023. Check out Janux Therapeutics' forecast to explore projected trends and price targets.

What is Janux Therapeutics's operating income?
Janux Therapeutics's total operating income in 2024 was -$98.85 million, based on the following breakdown:
  • Total Gross Profit: $10.59 million
  • Total Operating Expenses: $109.44 million
How has Janux Therapeutics revenue changed over the last 4 years?

Over the last 4 years, Janux Therapeutics' total revenue changed from $0.00 in 2020 to $10.59 million in 2024, a change of 1,058,800,000.0%.

How much debt does Janux Therapeutics have?

Janux Therapeutics' total liabilities were at $38.74 million at the end of 2024, a 7.4% increase from 2023, and a 319.6% increase since 2020.

How much cash does Janux Therapeutics have?

In the past 4 years, Janux Therapeutics' cash and equivalents has ranged from $7.81 million in 2020 to $430.61 million in 2024, and is currently $430.61 million as of their latest financial filing in 2024.

How has Janux Therapeutics' book value per share changed over the last 4 years?

Over the last 4 years, Janux Therapeutics' book value per share changed from -16.00 in 2020 to 19.49 in 2024, a change of -221.8%.


Related Companies

This page (NASDAQ:JANX) was last updated on 5/31/2025 by MarketBeat.com Staff
From Our Partners
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...
Porter & Company | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
Elon’s NEXT Big IPO?
Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...
Banyan Hill Publishing | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored